|St. Jude Medical Receives CE Mark Approval for World's Smallest, Longest-Lasting Rechargeable Deep Brain Stimulator for Parkinson's Disease|
First patient implanted with Brio neurostimulator at
Slightly larger than the typical man’s watch, the Brio neurostimulator has a thin 10 mm profile and weighs 29 grams (approximately 1 oz). Additionally, the device has the greatest recommended implant depth of any rechargeable DBS device. The thin profile and greater implant depth potentially makes the neurostimulator less noticeable and more comfortable for patients.
“Deep brain stimulation therapy is often the preferred treatment for
many Parkinson’s disease patients,” said Professor Dr.
The procedure was performed by Professor Sturm’s colleague, Dr.
The Brio DBS system delivers mild electrical pulses to specific targets in the brain, stimulating the structures that are involved in motor control. The system consists of a neurostimulator – a surgically implanted battery-operated device that generates the electrical pulses – and leads which carry the pulses to the brain to influence the irregular nerve signals responsible for the symptoms of Parkinson’s disease.
“The Brio neurostimulator is an important addition to our family of deep
brain stimulation systems,” said
In addition to its small size, the Brio neurostimulator has the longest battery life of any rechargeable DBS device currently on the market with a 10-year battery longevity approval. For patients this means the device should provide sustainable therapy and maintain a reasonable recharge interval for at least 10 years of use at high settings. The device’s battery longevity may also maximize the time between device replacement procedures.
The Brio neurostimulator also features:
Parkinson’s disease affects an estimated 6.3 million people worldwide,
according to the European Parkinson’s
This news release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995 that involve
risks and uncertainties. Such forward-looking statements include the
expectations, plans and prospects for the Company, including potential
clinical successes, anticipated regulatory approvals and future product
launches, and projected revenues, margins, earnings and market shares.
The statements made by the Company are based upon management’s current
expectations and are subject to certain risks and uncertainties that
could cause actual results to differ materially from those described in
the forward-looking statements. These risks and uncertainties include
market conditions and other factors beyond the Company’s control and the
risk factors and other cautionary statements described in the Company’s
filings with the
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6043641&lang=en